23 Jul, 2026
According to Straits Research, the global migraine with brainstem aura market size was valued at $6.77 billion in 2025 and is projected to grow from $7.13 billion in 2026 to $10.79 billion by 2034, registering a CAGR of 5.31% during the forecast period 2026–2034.
Migraine with Brainstem Aura, also called "basilar-type migraine" or "basilar migraine," is a rare subtype of migraine accompanied by an aura. Migraine is a neurologic condition characterized by frequent, intense migraines, which other symptoms may accompany. Migraine with Brainstem Aura is characterized by aura symptoms emanating from the brainstem, an essential anatomical region present at the base of the brain that controls a multitude of physiological processes.
Migraine with aura is a discrete subtype of migraine distinguished by the co-occurrence or precedence of visual, sensory, or other neurological disturbances while the convulsion stage is occurring. Other neurological disorders, including transient ischemic attacks (TIAs), may be mistaken for migraine with brainstem aura, an infrequent medical condition.
Migraine with brainstem aura is a recurrent condition that affects a subset of individuals, namely between 6.6% and 10% of patients diagnosed with migraine accompanied by aura. Migraine, when accompanied by a characteristic aura, is an exceptionally prevalent condition. A study published in May 2019 in the Journal of Headache and Pain reports that 8% of the general population is affected by migraine with aura.
Typical migraine aura (MA) symptoms consist of completely reversible visual, sensory, or linguistic disturbances. Visual aura symptoms (VASs) are the highest, comprising 98–99% of manifesting auras (MAs). In contrast, sensory and linguistic disturbances are observed in 36% and 10% of auras, respectively. Thus, the increasing incidence of migraine with aura will ultimately lead to a rise in cases of migraine with brainstem aura across the globe, thereby propelling the expansion of the global market.
Because of advancements in medical imaging technologies and the growth of the neuroscience field, the diagnosis of migraines with Brainstem Aura (MBA) has significantly advanced over the past ten years. Sophisticated neuroimaging techniques, such as diffusion tensor imaging (DTI) and functional magnetic resonance imaging (fMRI), were developed by scientists to assess and monitor the structure and activity of the brain throughout an MBA program. Functional MRI and diffusion MRI enhance the functionalities of magnetic resonance imaging (MRI) by acquiring intricate spatial images and, respectively, neuronal tracts and blood flow within the nervous system.
Additionally, regulatory approvals for the advancement of diagnostic devices of the major actors are growing in number. For instance, in May 2022, a leading provider of health technology worldwide, Royal Philips, revealed that their new MR 7700 3.0T MR system had received 510(k) approval from the FDA. The latest revolutionary MR innovation from Philips offers performance and precision that are unmatched in advanced clinical diagnostics and research. As a result, these factors are anticipated to generate expansion opportunities for the migraine with brainstem aura market.
North America holds the most significant market share during the forecast period. North America, particularly the United States and Canada, are widely recognized for their exceptionally sophisticated healthcare systems and profound understanding of medical concerns. This involves the collaboration between headache clinics and specialized neurologists with the ability to diagnose and treat migraines with brainstem aura. Migraine patients in North America who are afflicted with brainstem aura have access to a wide range of treatment options, including acute and preventative pharmaceuticals, non-pharmacological approaches, and preventative medications. The introduction of targeted migraine medications, such as calcitonin gene-related peptide (CGRP) inhibitors, has expanded the treatment options available to individuals suffering from migraines, including those with brainstem aura.
sales@straitsresearch.com